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We report a new theranostic device based on lead sulfide quantum dots (PbS QDs) with optical 
emission in the near infrared wavelength range decorated with affibodies (small 6.5 kDa protein-
based antibody replacements) specific to the cancer biomarker human epidermal growth factor 
receptor 2 (HER2), and zinc(II) protoporphyrin IX (ZnPP) to combine imaging, targeting and 
therapy within one nanostructure. Colloidal PbS QDs were synthesized in aqueous solution with a 
nanocrystal diameter of ~ 5 nm and photoluminescence emission in the near infrared wavelength 
range. The ZHER2:432 affibody, mutated through the introduction of two cysteine residues at the C-
terminus (Afb2C), was used as capping ligand to form Afb2C-PbS QDs which have a high binding 
affinity for HER2 which is overexpressed in several types of cancer including breast cancer. 
Afb2C-PbS QDs were further modified by conjugation with ZnPP, which acts as an anticancer 
agent. The biological activity of these QDs was tested against SKBR3 (HER2-positive) and MDA-
MB-231 (HER2-normal) breast cancer cells, with results showing that ZnPP-Afb2C-
functionalized PbS QDs were successfully targeted to the HER2-overexpressing cancer cells and 
induced cell apoptosis thanks to the conjugation with ZnPP. These results expand the use of the 
QD nanoplatform with the formulation of novel nanomaterials for targeted delivery and combined 
imaging and therapy via direct surface-protein interaction. 
  











































































The development of theranostic agents for simultaneous disease detection and targeted therapy has 
attracted considerable attention in recent years and brought significant advances to cancer 
treatments.1,2 This has been achieved by using drug delivery vehicles, such as polymer-based 
nanoparticles,3 protein nanocages,4 or liposomes, to encapsulate imaging and therapeutic agents, 
and also by direct attachment of ligands to the surface of solid colloidal nanoparticles (e.g. 
semiconductor quantum dots (QDs), silver, gold or iron oxide nanoparticles).5-7 In particular, the 
use of semiconductor QDs offers the benefit of tunable optical emission8 with in vivo imaging 
potential in the near-infrared (NIR) wavelength range where absorption of biological tissues is 
low. This is offered by QDs based on IV-VI group elements (PbS, PbSe).9-13 One of the areas 
where NIR-emitting nanomaterials are currently being investigated for detection and treatment is 
the targeting of breast cancers,14,15 exploiting the elevated expression of estrogen receptor alpha 
(ERα) and/or epidermal growth factor receptor 2 (HER2). Currently, focus has shifted towards 
HER2-based detection and therapy as this receptor is amplified or overexpressed in up to ~ 30% 
of breast cancers and other malignancies notably gastric cancers, while not expressed in 
immunohistochemically detectable quantities in normal adult tissue cells. HER2 overexpression is 
associated with poor prognosis in the absence of systemic therapy.16  
To date, molecules that have been explored for breast cancer-specific targeting include 
naturally recognized protein capsules, such as ferritin, and immunoglobulin G (IgG) antibodies.17-
19 A promising alternative are affibodies (Afb), which can replace antibodies as the targeting 
functionality of biopharmaceuticals for diagnostic and therapeutic applications.20,21 The ZHER2:432 
Afb is a non-immunoglobulin-based, highly specific binding protein of small size (58 amino acids, 
~6.5 kDa), engineered from a 3-helix bundle Z derived from staphylococcal protein A, with a high 
binding affinity for HER2 (KD ~22 pM).
22,23 It is known for fast and reversible folding, high 










































































solubility in aqueous solutions, an attachment surface as large as an antibody antigen binding 
pocket and for being easily expressed in high yields in E. coli, thus making it an ideal targeting 
agent for cancer therapies,24-26 which is slowly making its way in theranostic applications.27 The 
immobilization of Afb’s was recently demonstrated on nanoparticles, including Ag2S and 
InAs/InP/ZnSe core/shell/shell QDs through the use of a heterobifunctional linker conjugation on 
PEG-capped QD surfaces, or via electrostatic interactions,28-30 but no direct surface attachment has 
been reported to date. 
Current breast cancer therapy comprises several partially successful drugs; however, new 
therapeutic strategies are needed, especially for metastatic and drug-resistant breast cancers.31,32 
Recently, the therapeutic anticancer activity of zinc(II) protoporphyrin IX (ZnPP) was 
demonstrated with the inhibition of hemeoxygenase-1,33,34 an enzyme which is highly 
overexpressed in cancerous tissues and exerts a cytoprotective effect by neutralizing oxidative 
stress in cells.35 At the same time, ZnPP can also induce cell apoptosis by generating singlet oxygen 
species upon irradiation with blue light (λex = 425 nm), allowing for applications in cancer 
photodynamic therapy.36-39 Despite the number of promising advances, including nano-
engineering of drug delivery systems40 as well as surface decoration of QDs41 combined targeting, 
anticancer activity and imaging within one nano-construct is yet to be achieved. Facile procedures 
for the controllable and direct attachment of targeting and therapeutic agents onto the QDs surface 
still remain challenging.  
In this work we describe a one-pot synthesis of water-soluble and biocompatible near-
infrared-emitting PbS QDs functionalized with Afb and ZnPP for diagnosis and therapy (Figure 
1a). The simultaneous attachment of both ZHER2:432 Afb and ZnPP molecules onto a QD surface 
will produce a novel theranostic agent that combines the benefits of selective targeting and specific 









































































cellular uptake induced by Afb, the NIR fluorescent bioimaging of QDs and the anticancer activity 
of ZnPP. The ZHER2:432 Afb was genetically modified to introduce two specific mutations to 
incorporate two cysteine residues at its C-terminus – G82C and S83C. The Afb2C generated with 
two thiol groups allows for a bidentate interaction of the protein with the QD and consequently 
stronger binding to the QD surface, hence increasing the long-term stability of the QD-protein 
conjugate.39 Afb2C-PbS QDs were further modified by conjugating ZnPP at the lysine residues of 
Afb2C to produce ZnPP-Afb2C-PbS QDs, which were found to be stable in solution and optically 
active in the NIR. The effect of these QDs on HER2-overexpressing (HER2+) SKBR3 cells was 
explored to confirm selectivity and activity and is reported herein. The approach reported here for 
the synthesis of novel nanocomposites that combine in one structure targeting, imaging and 
therapy is relevant for the advancement of theranostics into the clinic.  
 
Results and discussion 
Site-directed mutagenesis was performed to create a specific change on the ZHER2:342 
affibody (Afb) DNA sequence. In the pJexpress401 plasmid, the Afb2C gene was designed with 
an N-terminal His-tag, and two mutations (G82C and S83C) which were introduced at its C-
terminus; we note that these residues were not critical for the Afb binding to HER2 (Supplementary 
Information, SI1). The mutant Afb2C protein was successfully expressed in BL21 (DE3) E. coli 
and purified using nickel(II)-immobilized metal affinity chromatography (IMAC) followed by 
further purification by size exclusion chromatography (SEC). The presence and purity of the 
Afb2C protein were confirmed by Tris-glycine (Tricine)-SDS-PAGE. To examine the stability of 
the Afb2C structure under the conditions used for QD synthesis, the secondary structure of the 
Afb2C protein was determined at pH 7.0 and pH 11.0 using circular dichroism (CD) spectroscopy 








































































(see Supplementary Information, Figure S2), indicating that the α-helical secondary structure of 
the Afb2C found at pH 7.0 was retained at pH 11.0.  
The Afb2C was used as the capping ligand in a one-pot synthesis of PbS QDs. The QDs 
were synthesized in aqueous solution following modified procedure reported in Refs [11, 13] with 
molar ratio of Pb:S = 1:0.3 (Figure 1a). In this process, the presence of two cysteine sites in Afb2C 
offers bidentate interaction with the QD surface and greater stability, as was previously 
demonstrated for other bidentate ligands such as dihydrolipoic acid.42 Then, ZnPP was conjugated 
in situ to Afb2C-PbS QDs by reacting the lysine residues located within the Afb2C protein with 
the NHS-activated carboxyl groups on the protoporphyrin, forming a stable amide bond – we did 
not investigate further which lysines had been involved in the process. Figure 1b shows the native 
agarose gel electrophoresis spots of Afb2C-PbS QDs and the ZnPP-Afb2C-PbS QDs. Under 
illumination with UV light ( =  −  nm), no fluorescent bands were observed on native 
PAGE gels of Afb2C-PbS QDs as these emit in the NIR region, while clear red fluorescence was 
observed for ZnPP-Afb2C-PbS QDs, as expected from the presence of ZnPP, confirming 
successful conjugation (Figure 1b). We also explain the lower migration spot for ZnPP-Afb2C-
PbS QDs with their faster migration compared to Afb2C-PbS QDs, due the change in net charge 
(pI) derived from the neutralization of lysine residues after conjugation, despite their overall larger 
size.  
The synthesized QDs have room temperature photoluminescence (PL) centered at λPL 
~1180 nm (Figure 1d), similar to that expected from this synthesis method with 
thioglycerol/dithioglycerol capping ligands, and suggest that the Afb2C can be used instead of 
dithioglycerol to provide efficient passivation of the QD surface. Significantly, attachment of 
ZnPP does not affect the optical properties of the QDs.11,43 We note that the presence of both 










































































Afb2C and ZnPP on the QD surface provides more efficient surface passivation and greater 
stability against Ostwald ripening, compared to Afb2C only passivated QDs. Both QD solutions 
have comparable PL peak position for the fully ripened samples (Figure 1d). The TEM images 
revealed that the PbS QDs had a spherical shape, high crystallinity and an average diameter of 51 
nm (Figure 1c and Supplementary Information, Figures S3, S4), with the observed size comparable 
to that estimated from the PL peak position using model developed by Moreels et al.44 Both 
Afb2C-PbS QDs and ZnPP-Afb2C-PbS have long term colloidal stability with respect to 
morphological and optical properties over a period of at least three months (stored under nitrogen 
at T = 4 °C). 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used 
to study the growth inhibitory effects of Afb2C-PbS QDs and ZnPP-Afb2C-PbS QDs in SKBR3 
and MDA-MB-231 cell lines. SKBR3 is a human breast cancer cell line expressing between 
1,000,000 and 2,000,000 HER2 per cell, whereas non-cancerous cells display ~20,000 HER2 per 
cell.45,46 Consequently, the SKBR3 cell line is used as a positive control in HER2 assays and is 
considered a suitable preclinical model for screening therapies that target HER2.45,46 Clinically, 
HER2+ breast cancers develop resistance to trastuzumab (Herceptin®), the therapeutic antibody 
developed to target and treat this type of breast.32 MDA-MB-231 triple negative breast cancer 
(TNBC) cells, instead, display ~100-fold lower HER2. Also lacking estrogen and progesterone 
receptors, TNBCs are associated with poor prognosis, exhibiting highly invasive characteristics. 
47,48 Following 72 h exposure, dose-dependent growth inhibition was observed in SKBR3 cells in 
the presence of Afb2C-PbS QDs, with a mean GI50 value of 26 µg/mL (Afb2C concentration 4.5 
mg/ml during synthesis), which is significantly lower than that observed for Afb2C alone and 
ZnPP alone (GI50 > 100 µg/mL, Figure 2 and Supplementary Information, Figure S5);
 37 no growth 










































































inhibitory effects were observed in MDA-MB-231 cells < 100 µg/mL (Figure 2 and 
Supplementary Information, Figure S5). These results suggest that the Afb2C is recognized by 
HER2 receptors as predicted and leads to selective and enhanced uptake of the nanoplatform in 
the HER2+ SKBR3 cells. In this case the activity is due to the presence of PbS QDs, which have 
been shown previously to be non-toxic to normal cells (MRC-5) but to induce cytotoxic effects in 
cancerous cells.11 Comparable results are observed following exposure to ZnPP-Afb2C-PbS QDs 
(Figure 2 and Supplementary Information, Figure S6). The lower GI50 value in SKBR3 cells 
confirms Afb-induced targeting. We note that the greater growth inhibition observed in MDA-
MB-231 exposed to ZnPP-Afb2C-PbS, compared to Afb2C-PbS only, is likely due to extracellular 
activity of ZnPP conjugated on our nanoplatform, as this is able to generate ROS and inhibit 
hemeoxygenase-1 and acts as photosensitizer. 34,37,38  It was shown previously that the anticancer 
activity of ZnPP is different in different cell lines and can be enhanced, e.g. by pre-treatment of 
cancer cells with agents affecting protein transportation. 39 
To investigate further the nature of growth inhibitory activity, we performed cell cycle 
studies in SKBR3 cells. SKBR3 cells were exposed to Afb2C-PbS QDs or ZnPP-Afb2C-PbS QDs 
at a concentration of 2× GI50 value for 24 h, 48 h, and 72 h. The flow cytometry results (Figure 3a 
and S7) revealed increasing populations in the pre-G1 phase with increasing exposure time. For 
Afb2C-PbS QDs the pre-G1 population increased from 13.3% after 24 h to 52.3% (P < 0.0001) 
after 72 h of treatment, and was accompanied by decreased G1, S and G2/M events (Figure 3b). 
Similar changes were observed for ZnPP-Afb2C-PbS QDs, where the cell population in pre-G1 
phase increased from 18.9% to 52.8% after 72 h treatment (Figure 3b). The presence of significant 
pre-G1 events is indicative of DNA degradation and consequent cell apoptosis, previously reported 
following cancer cell exposure to PbS QDs.11 Resistance to apoptosis is a hallmark of human 










































































cancer,49 thwarting successful treatment; therefore, inducing apoptosis in cancer cells is a major 
goal of anticancer therapies. We expected that ZnPP-Afb2C-PbS QDs would exhibit augmented 
anti-proliferative effects due to conjugation with ZnPP, however, Afb2C-PbS QDs and ZnPP-
Afb2C-PbS QDs had similar effects on the SKBR3 cell cycle. Our results suggest that conjugation 
of ZnPP with Afb2C-PbS QDs decreases the affinity of Afb for HER2 receptors and consequently 
reduces the effects of ZnPP-Afb2C-PbS QDs on HER2+ SKBR3 cells. The reduced dose of ZnPP-
Afb2C-PbS QDs in these cells is therefore responsible for their similar growth inhibitory effect to 
Afb2C-PbS QDs. 
Further flow cytometric studies were performed to investigate the mechanism of cell death, 
using dual propidium iodide (PI) and annexin V staining of cells. The results confirmed cell death 
by apoptosis (early- and late-stage) for Afb2C-PbS QDs and late-stage apoptosis-detection for 
ZnPP-Afb2C-PbS QDs following exposure to 2× GI50 for 24 h, 48 h and 72 h, where apoptotic 
populations gradually increased with time to >20% (Supplementary Information, SI2). Afb2C-PbS 
QDs induced late apoptosis in SKBR3 cells after 24 h of treatment and their effect increased by 
44% after 72 h. In addition, SKBR3 cell necrosis was also detected after 72 h of treatment: we 
conclude that Afb2C-PbS QDs induced SKBR3 cell apoptosis and necrosis, the major cell death 
pathways. For ZnPP-Afb2C-PbS QDs, cells underwent necrosis after 24 h of exposure, doubling 
to 23.1% after 72 h of treatment (Supplementary Information SI2, Figure S11). This indicates that 
the nanocomposites have a potent anti-proliferative effect on SKBR3 cells and that they force most 
cells to undergo necrosis bypassing programmed cell death: we conclude that conjugation of ZnPP 
with Afb2C-PbS QDs switches SKBR3 cell fate from apoptosis to necrosis, suggesting a sudden 
catastrophic cytotoxic effect for this nanocomposite compared to Afb2C-PbS QDs. 








































































The ability of ZnPP-Afb2C-PbS QDs to enter and localize in cells was monitored using 
flow cytometry in SKBR3 and MDA-MB-231. Cells were incubated with ZnPP-Afb2C-PbS QDs 
at 2× GI50 for 3 h. The uptake of ZnPP-Afb2C-PbS QDs was ~2-times higher in HER-2+ SKBR3 
cells compared to MDA-MB-231 cells (Supplementary Information, SI3).  
Confocal microscopy imaging was used to detect intracellular fluorescence of ZnPP-
Afb2C-PbS QDs (λem= 593 nm, excitation with 425 nm, Figure 4 and Supplementary Information, 
SI3) and indicated that the agent is distributed in the cell cytoplasm; the non-uniform fluorescence 
with small brighter areas suggests uptake by endocytosis. Despite reporting significant agent 
uptake, no detectable fluorescence was measured in MDA-MB-231 cells by confocal microscopy 
(Supplementary Information, Figure S13): we explain this fact with the presence of ZnPP that 
leads to cell death, as reported previously, 37 a consequence of high metabolic turnover and genetic 
instability, making cells more susceptible to ROS generation and its consequences. Confocal 
images also revealed changes in morphology of both studied cell lines following treatment with 
ZnPP-Afb2C-PbS QDs, such as blebbing of the cell membrane, which is associated with late-stage 
apoptosis and necrosis; that this has occurred is strongly indicated by intracellular PI accumulation 
observed in flow cytometric assays, and corroborates an apoptotic mechanism of cell death.  
In our recent work, we demonstrated deep tissue imaging with near-infrared PbS QDs.13 
The results in the present report on novel PbS QDs directly coated with the anti-HER2 Afb2C 
protein and conjugated with ZnPP indicate realistic prospects for their utilization in cancer imaging 
and therapy. The enhanced uptake demonstrated for Afb2C-functionalized nanoparticles is of 
benefit for drug delivery and imaging of HER2-overexpressing cancer cells.50 With the present 
report, we have also demonstrated the possibility of using the QDs’ surface for the direct 
incorporation of other active principles within the same nanostructure for theranostic applications, 









































































which could be expanded to other agents, e.g. the therapeutic antibodies pertuzumab and 
trastuzumab.50  
In conclusion, we have produced stable near-infrared colloidal PbS QDs directly passivated 
with a small protein Afb2C and further functionalized with ZnPP. The Afb2C provides targeting 
to the HER2+ cells while ZnPP contributed therapeutic activity against breast cancer cells. The 
novel theranostic ZnPP-Afb2C-PbS QDs demonstrated selective anticancer activity, targeting 
HER2+ cells and triggering apoptotic cell death; the bioimaging application has also been reported 
in vitro, and further studies are required to assess the activity of these QDs in vivo and to explore 
their theranostic potential. 
 
Materials and methods 
DNA mutagenesis: DNA sequence gene encoding Afb in pJexpress401 plasmid was mutated by 
replacing glycine and serine at positions 82 and 84 respectively with cysteine using Q5® Site-
Directed Mutagenesis according to the manufacturer's instructions (New England Biolabs) to 
produce Afb2C. Afb2C in pJexpress401 plasmid was amplified by transforming in the DH5 
calcium competent cells and then the plasmid was extracted and purified using the Wizard Plus® 
SV Miniprep kit (Promega).  
Afb2C expression and purification: For the Afb2C expression, isopropyl β-D-1-
thiogalactopyranoside (IPTG) (1 mM, Fisher Scientific) was added for 4 h at T = 37 °C into E. coli 
BL21 (DE3) culture containing the pJexpress401:Afb2C plasmid. The Luria Bertani (LB) medium 
supplemented with kanamycin (50 μg /mL, Apollo Scientific) was used. Cells were collected by 
centrifugation (2500 g, 25 min, T = 4 °C), resuspended in binding buffer (40 mL of 20 mM Tris 
pH 8.3 (Fisher Scientific), 10 mM imidazole (Sigma Aldrich)), 1 mM phenyl methyl sulfoxide 










































































(PMSF) (Sigma Aldrich)) and sonication. The sample was then centrifugation (35000 g, 25 min, 
T = 4 °C) and the supernatant was loaded on a 5 mL nickel column (GE Healthcare). 5mL of 
binding buffer (20 mM of Tris pH 8.6, 10 mM of imidazole) was used for washing; washing was 
repeated 3-times. Afb2C was then eluted using a linear gradient of increasing imidazole 
concentration up to 500 mM. The purified Afb2C was loaded into 6-8 K MWCO dialysis tubing 
(Spectrum Laboratories) and dialyzed against two changes of Tris buffer (2 L, 20 mM Tris pH 8.3, 
1 mM DTT) for ~16 h. Tricine-SDS-gel electrophoresis was used to confirm presence of Afb2C. 
All fractions containing Afb2C were loaded on a size exclusion column (Superdex 75 10/300 GL) 
and were analyzed using Tricine-SDS-PAGE. NANO Drop A-1000 spectrophotometer was used 
to measure the absorbance of the samples (extinction coefficient = 8,480 M cm-1), which were 
used to calculated the concentration of Afb2C. The yield of purified protein was 4 mg per L of 
culture. 
MALDI-TOF MS: Bruker Matrix Assisted Laser Desorption/Ionization (MALDI-TOF, 
Bruker Ultraflex III) MS was used to analyze the samples following the LP-44 kDa 
method. Samples were prepared by mixing 5 µL of protein with 10 µL of the saturated 
sinapic acid solution (molar ratio of sinapic acid to acetonitrile is 1:2, with added 0.1% 
(v/v) of trifluoroacetic acid). Samples were loaded onto the plate and dried at room 
temperature. The spectrum was analyzed using flexControl (Ultraflex) 3.0 software. 
Circular dichroism (CD) spectroscopy. The Afb2C (0.5 µg/mL) was analyzed in 20 
mM Tris buffer at pH 7.0 and pH 11.0 using a CD spectrometer (Chirascan Plus 
Spectroscopy). Samples were dialyzed with the desired buffer at 4 ºC overnight and the 
pH was adjusted using 10 mM H2SO4. 










































































Synthesis of Afb2C-PbS QDs: Afb2C in 70% (v/v) (NH4)2SO4 was pelleted and washed 
with Tris buffer (20 mM Tris pH 8.3) including 70% (v/v) (NH4)2SO4 and pelleted 
again to remove the DTT. The pellet was dissolved in 1.7 mL of 0.0167 M aqueous 
solution of lead acetate trihydrate (Pb(CH3CO2)2.3H2O) (Sigma), and 1.7 mL of Tris 
buffer (40 mM Tris pH 8.3) was added. The pH was adjusted to 11.0 using 0.1 M 
NaOH. The reaction mixture was stirred for 30 minutes under N2. Then 0.25 mL of 0.1 
M Na2S was added to the reaction mixture. The color of the solution changed to dark 
brown indicating the formation of PbS QDs. The Afb2C-PbS QDs solution was stirred 
for 30 minutes. Finally, the product was dialyzed against Tris buffer (20 mM Tris pH 
11.0) overnight to remove excess reactants. The QD solutions were stored under a 
nitrogen atmosphere at 4 ºC in the dark. 
Labelling of Afb2C-PbS QDs with ZnPP: Afb2C-PbS QDs were dialyzed against PB 
(20 mM NaH2PO4 pH 11.0) overnight at 4 ºC. ZnPP labelling was performed modified 
Thermo Scientific protocol. To produce the activated protoporphyrin-N-
hydroxysuccinimide ester (ZnPP-NHS), 100 µL of ZnPP in DMSO (30 mM) were 
mixed with 12 µL of 500 mM of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (EDC) in MES buffer (0.1 M MES (2-[N-morpholino]ethanesulfonic 
acid) pH 6). The reaction mixture was agitated at room temperature for 1 minute. 
Following incubation, 12 µL of N-hydroxysuccinimide (NHS) (500 mM) in MES 
buffer was added. The reaction mixture was agitated for further 15 minutes at room 
temperature before the solution was centrifuged at room temperature (4000 g, 15 
minutes) and any precipitates were discarded. Afb2C-PbS QDs were mixed with a 10-
fold excess of the activated ZnPP-NHS ester under ambient conditions. The reaction 








































































mixture was protected from light and was gently agitated overnight at room 
temperature. The product was centrifuged at 5000 g for 10 minutes to remove 
unreacted protoporphyrin and then dialyzed against PB (20 mM NaH2PO4 pH 8.3) 
overnight at 4 ºC. The QD solutions were stored under a nitrogen atmosphere at 4 ºC in 
the dark. 
Optical and morphological characterization: The PL of PbS QDs was analyzed using a 
Horiba Jobin Yuon Ltd HR800 LabRam setup equipped in InGaAs detector. The 
excitation was provided with a He-Ne laser (λ = 633 nm, P = 104 W/cm2). For 
transmission electron microscopy (TEM) studies, PbS QDs at a concentration of 0.1 
mg/mL were deposited on a graphene-oxide-coated Cu grid (Agar Scientific) and TEM 
images were recorded on the JEOL2100EX microscope operating at 120 keV.  
In vitro studies: SKBR3 and MDA-MB-231 breast cancer cell lines were cultured 
under optimum conditions in RPMI nutrient medium (Sigma-Aldrich) supplemented 
with 10% fetal bovine serum (FBS; Sigma Aldrich), and sub-cultivated twice weekly to 
maintain logarithmic growth. For MTT assays, cells were seeded into 96-well plates at 
a density of approximately 3 x 103 cells/well in 180 µL medium and allowed to adhere 
to the plates by incubating at 37 ˚C for 24 h. Serial dilution of Afb2C-PbS QDs or 
ZnPP-Afb2C-PbS QDs were prepared and 20 µL per well was added to achieve a final 
concentration of Afb2C from 0.1 g/mL to 120 g/mL. After 72 h exposure, MTT 
solution (50 µL 2 mg/mL) was added to each well and incubated for 3 h. The medium 
was aspirated and DMSO (150 µL) was added to dissolve the formazan crystals. The 
absorbance was measured at 550 nm using an En Vision 2104 Multilabel microplate 
reader (PerkinElmer). 










































































For cell cycle and Annexin V assays, cells were seeded in a 6-well plate at a density of 
7.5 x 104 cells/well in 2 mL of RPMI nutrient medium supplemented with 10% FBS, 
and allowed 24 h to adhere. The cells were treated with 2x GI50 concentrations of 
Afb2C-PbS QDs and ZnPP-Afb2C-PbS QDs for 24 h, 48 h and 72 h. The medium, 
containing dead cells, was collected into labelled fluorescence activated cell sorter 
(FACS) tubes and kept on ice. The remaining adherent cells were trypsinized with 500 
µL of 1 x trypsin-EDTA before pooling with the medium containing dead cells. The 
cells were centrifuged at 4 ºC (1200 rpm) for 5 minutes, the supernatant was removed, 
and the cell pellets washed with 1 mL of PBS followed by another cycle of 
centrifugation. The supernatant was decanted.  
For cell cycle assays, cell pellets were resuspended in 500 μL of cold hypotonic 
fluorochrome solution (50 μg/mL PI (Sigma-Aldrich), 0.1 mg/mL ribonuclease A 
(Sigma-Aldrich), 0.1% v/v Triton X-100 (Sigma-Aldrich), 0.1% w/v sodium citrate 
(Sigma-Aldrich) dissolved in PBS), protected from light and stored overnight at 4 ºC. 
Samples were vortexed and analyzed on a Beckman Coulter Epics-XL MCL flow 
cytometer. At least 10 000 events were recorded for each sample. The results were 
analyzed using EXPO32 software. 
For annexin V assays, the Annexin V-FITC/PI (AV/PI) (BD Pharmingen) kit was used. 
To FACS tubes containing cell pellets, 400 μL of 1 x annexin binding buffer and 10 μL 
of PI solution were added, samples were vortexed and incubated for 10 minutes at 
room temperature without light. Samples were analyzed within 1 h on a Beckman 
Coulter Epics-XL MCL flow cytometer and at least 10 000 events were recorded for 
each sample. The results were analyzed using EXPO32 software. 









































































The cellular uptake of ZnPP-Afb2C-PbS QDs was studied using flow cytometry. Cells 
were seeded at a density of 7.5 x 104 cells/well in 6 well plates in 2 mL of RPMI 
nutrient medium and allowed 24 h to adhere. The cells were treated with 2 x GI50 
concentration of ZnPP-Afb2C-PbS QDs for 3 h. The cells were then washed (2-times 2 
mL of PBS), trypsinized (0.5 mL 0.25% w/v trypsin-EDTA), pooled (1 mL RPMI 
nutrient medium) and centrifuged for 5 minutes at 1200 g (Beckman Coulter Allegro). 
The cell pellet was further washed (2x 1mL PBS), centrifuged and resuspended in 0.5 
mL of PBS. Astrios EQ flow cytometer (Beckman Coulter) with excitation at λex = 425 
nm and Kaluza Flow Cytometry software were adopted for analysis . 
Confocal microscopy: Cells were seeded in an 8-well µ-slide confocal chamber (Ibidi 
GmbH, Munich, Germany) at a density of 7.5 x 104 per well. After overnight 
incubation, cells were treated with before treatment with 2 x GI50 of ZnPP-Afb2C-PbS 
QDs. After 24 h exposure, cells were washed (3x 0.2 mL PBS), fixed (0.2 mL 4% (v/v) 
formaldehyde, 20 minutes), then washed again (3x 0.2 mL PBS). Fixed cells were 
stained with DRAQ5™ DNA stain, then washed (3x 0.2 mL PBS). Confocal 
microscopy images were captured on LEICA DMI 4000 B using excitation 
wavelengths λex = 425 nm and λem = 593 nm. ImageJ (Fiji) software was used for image 
analysis. 
Statistical analysis: For all experiments, n ≥ 3 internal replicates and n ≥ 3 independent trials were 
conducted. Data were analyzed using one-way, two-way analyses of variance (ANOVAs), and t-
tests; p < 0.05 identified significance.  
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Figure 1. a) A cartoon of the formation of ZnPP-Afb2C-PbS QDs. b) A native agarose gel 
electrophoresis of Afb2C-PbS and ZnPP-Afb2C-PbS QDs; (right) the gel under UV light (λex=300-
400 nm) and (left) gel under visible light. The agarose gel was prepared with a low percentage 
agarose (0.5% w/v), and the samples were electrophoresed at 100 V for 1 hours. c) A representative 
HR TEM image of Afb2C-PbS QDs. d) Room temperature PL spectra of PbS QDs capped with 
Afb2C (red) and with ZnPP-Afb2C (black) for freshly prepared samples (continuous line) and 











































































































Figure 2. Results of the MTT assays for a) MDA-MB-231 and b) SKBR3 cells following 72 hours 
treatment with Afb2C alone, Afb2C-PbS QDs and ZnPP-Afb2C-PbS QDs. n = 6; experiments 
were repeated 3 times, and all data point are show with standard deviation. 
  

















































































































































Figure 3. Cell cycle analysis for SKBR3 cells. SKBR3 cells were seeded at a density of 7.5 × 104 
cells/well in 6-well plates and incubated for 24 hours before treatment with either Afb2C-PbS QDs 
and ZnPP-Afb2C-PbS QDs at 2x GI50 for 24 hours, 48 hours, and 72 hours. * indicates significant 
difference compared to control ** (P<0.1), ***(P<0.001) and ****(P<0.0001). n = 2; experiments 
were repeated 3 times. a) Histograms show the time-dependent response of control (untreated) 
cells and 24 h, 48 h, and 72 h exposure to Afb2C-PbS QDs. b) Programmed cell death analysis of 























































































































































































































































Figure 4. Confocal images. a) is the brightfield view while b) shows the fluorescence emitted 
from SKBR3 cells after exposure to ZnPP-Afb2C-PbS QDs for 3 h. Fluorescence was not observed 
from untreated SKBR3 cells, where c) is the brightfield channel and d) the fluorescence one. Cells 
were seeded at a density of 10 × 103 cells/well in 8-well plate and treated with ZnPP-Afb2C-PbS 
QDs at 2× GI50. For both experiments, ZnPP was excited at 425 nm and the emitted light was 
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